Showing 7101-7110 of 8886 results for "".
- PCA Skin Rings in the Fourth Annual National Peel Dayhttps://practicaldermatology.com/news/pca-skin-rings-in-the-fourth-annual-national-peel-day/2461598/March 10, 2023 is the fourth annual National Peel Day, created by PCA SKIN. "National Peel Day was established in 2020 to drive awareness, increase education, and demystify misconceptions around the non-invasive treatment,” says Joanna Zucker, CEO CP Skin Health Group US
- Landmark Data: Neoadjuvant Pembrolizumab Improves Outcomes for High-risk Melanoma Patientshttps://practicaldermatology.com/news/landmark-data-neoadjuvant-pembrolizumab-improves-outcomes-for-high-risk-melanoma-patients/2461589/Patients with high-risk melanoma who received pembrolizumab both before and after surgery had a significantly lower risk of their cancer recurring than patients who received the drug only after surgery. These results, published today in the
- Dyskerin May Signal When SCC Is On The Movehttps://practicaldermatology.com/news/dyskerin-may-signal-when-scc-is-on-the-move/2461585/The protein dyskerin may provide important clues as to how cutaneous squamous cell carcinoma tumors prepare themselves to migrate to the lymph nodes to metastasize other organs, a new study suggests. These cells stop consuming glucose so that they can survive by using LDL chol
- Baby Dove Launches #BabySkin Advice on TikTok with Top Dermatologists and Pediatricianshttps://practicaldermatology.com/news/baby-dove-launches-babyskin-advice-on-tiktok-with-top-dermatologists-and-pediatricians/2461582/Baby Dove is launching #BabySkin Advice,' on TikTok The series provides expert advice from dermatologists and pediatricians to help parents in search of trusted products to care for their newborns unique and delicate skin needs. The #BabySkin Advice series will run from&n
- Boehringer Ingelheim, FIT Join Forces to Raise GPP Awarenesshttps://practicaldermatology.com/news/boehringer-ingelheim-fit-join-forces-to-raise-gpp-awareness/2461581/Boehringer Ingelheim is teaming up with the Fashion Institute of Technology (FIT) in New York to extend The Unwearable Collection, a four-piece art collection that illustrates the physical and emotional burden of generalized pustular psoriasis (GPP). Over the course of the partner
- BeautyHealth Acquires SkinStylushttps://practicaldermatology.com/news/beautyhealth-acquires-skinstylus/2461579/The Beauty Health Company is set to acquire SkinStylus, a US Food and Drug Adminstrayion -cleared microneedling device. The agreement represents a key step forward in BeautyHealth’s portfolio build-up strategy. Upon successful integration of SkinStylus into the BeautyHealth
- Garnier Nutrisse Announces Drew Barrymore as Brand Ambassadorhttps://practicaldermatology.com/news/garnier-nutrisse-announces-drew-barrymore-as-brand-ambassador/2461577/Drew Barrymore is the new brand ambassador for Garnier Nutrisse, an expansion to her current role with the Garnier portfolio. Barrymore's role debuts with a creative campaign highlighting Garnier Nutrisse's new and improved Nourishing Color Crème formula for nourished hai
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-gener
- Study: Psoriasis Medicine May Help Treat Alcohol Use Disorderhttps://practicaldermatology.com/news/psoriasis-medicine-may-help-treat-alcohol-use-diisorder/2461571/Apremilast may be an “incredibly promising” treatment for alcohol use disorder, according to a new study in the Journal of Clinical Investigation. On average, the people who took apremi
- Aldeyra Therapeutics Advances Investigational ADX 629 Into Phase 2 Trial for Atopic Dermatitishttps://practicaldermatology.com/news/aldeyra-therapeutics-advances-investigational-adx-629-into-phase-2-trial-for-atopic-dermatitis/2461568/Aldeyra Therapeutics announced the initiation of Phase 2 clinical trials evaluating the safety and efficacy of ADX‑629, an investigational oral RASP modulator, for the treatment of several systemic diseases, including atopic dermatitis. For the atopic dermatitis indication, the mul